The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
DAAs
HCV elimination
break-even
hepatitis C infection
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
21
01
2021
received:
30
06
2020
accepted:
24
01
2021
pubmed:
3
2
2021
medline:
24
4
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID-19) was also developed. The estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20-year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015-2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients treated during 2017-2019. The cost-savings ranged from € 45 to € 275 million. The investment needed to expand access to DAAs in 2015-2019 is estimated to be recovered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years in Spain. A delay in treatment because of COVID-19 will increase liver mortality in all countries. Direct-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts.
Sections du résumé
BACKGROUND AND AIMS
We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain.
METHODS
An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus disease (COVID-19) was also developed.
RESULTS
The estimated number of avoided hepatocellular carcinoma, decompensated cirrhosis and liver transplantations over a 20-year time horizon was: 1,057 in England; 1,221 in Italy; 1,211 in Romania; and 1,103 in Spain for patients treated during 2015-2016 and 640 in England; 626 in Italy; 739 in Romania; and 643 in Spain for patients treated during 2017-2019. The cost-savings ranged from € 45 to € 275 million. The investment needed to expand access to DAAs in 2015-2019 is estimated to be recovered in 6.5 years in England; 5.4 years in Italy; 6.7 years in Romania; and 4.5 years in Spain. A delay in treatment because of COVID-19 will increase liver mortality in all countries.
CONCLUSION
Direct-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts.
Identifiants
pubmed: 33529499
doi: 10.1111/liv.14808
pmc: PMC8248004
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
934-948Subventions
Organisme : Italian Ministry of Health
ID : RF-2016-02364053
Organisme : University of Tor Vergata Rome
Informations de copyright
© The Authors. Liver International published by John Wiley & Sons Ltd.
Références
PLoS One. 2017 Oct 4;12(10):e0185728
pubmed: 28977040
Dig Liver Dis. 2020 Sep;52(9):947-949
pubmed: 32527655
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Hepatology. 2011 Aug;54(2):396-405
pubmed: 21520194
Hepatology. 2013 Jun;57(6):2164-70
pubmed: 23280550
Gastroenterology. 2012 Oct;143(4):974-85.e14
pubmed: 22863764
BMC Public Health. 2009 Jan 22;9:34
pubmed: 19161623
J Viral Hepat. 2015 Feb;22(2):175-83
pubmed: 25040391
Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1473-83
pubmed: 23111959
Eur J Intern Med. 2018 Jul;53:79-84
pubmed: 29475770
Health Technol Assess. 2006 Jul;10(21):1-113, iii
pubmed: 16750059
J Viral Hepat. 2004 Mar;11(2):166-74
pubmed: 14996352
Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):303-314
pubmed: 29300496
Eur Rev Med Pharmacol Sci. 2015;19(9):1610-20
pubmed: 26004601
Cost Eff Resour Alloc. 2017 Jul 21;15:15
pubmed: 28736505
J Gastrointestin Liver Dis. 2010 Dec;19(4):373-9
pubmed: 21188327
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):363-374
pubmed: 30351994
Gastroenterol Hepatol. 2017 Aug - Sep;40(7):433-446
pubmed: 28645446
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Clin Drug Investig. 2016 Aug;36(8):661-72
pubmed: 27234943
Med Clin (Barc). 1996 Sep 21;107(9):331-5
pubmed: 8984235
Liver Int. 2020 Mar;40(3):522-529
pubmed: 31815353
Gut. 1999 Apr;44(4):563-7
pubmed: 10075966
N Engl J Med. 1995 Jun 1;332(22):1463-6
pubmed: 7739682
Clin Infect Dis. 2020 Apr 13;:
pubmed: 32282879
Pharmacoeconomics. 2019 Feb;37(2):255-266
pubmed: 30378086
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37
pubmed: 23460056
Hepatology. 2000 Jul;32(1):91-6
pubmed: 10869294
Gut. 2015 Aug;64(8):1277-88
pubmed: 25311032
Epidemics. 2021 Mar;34:100442
pubmed: 33607538
Liver Int. 2020 Jul;40(7):1545-1555
pubmed: 32078234
J Viral Hepat. 2021 Jun;28(6):859-869
pubmed: 33599365
Liver Int. 2021 May;41(5):934-948
pubmed: 33529499
Farm Hosp. 2014 Sep 16;38(5):418-29
pubmed: 25344136
Hepatology. 2017 Dec;66(6):1814-1825
pubmed: 28741307
Hepatology. 2008 Aug;48(2):418-31
pubmed: 18563841